Taxanes: Vesicants, irritants, or just irritating?

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 1, 2014, Pages 16-20

  Barbee, Meagan S ^a   Owonikoko, Taofeek K ^b   Harvey, R Donald ^b  

^a MERCER UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

cabazitaxel; docetaxel; extravasation; irritant; paclitaxel; taxane; vesicant

Indexed keywords

ANTINEOPLASTIC AGENT; CABAZITAXEL; DOCETAXEL; IRRITANT AGENT; PACLITAXEL; RICINOMACROGOL; TAXANE DERIVATIVE;

DNA DAMAGE; DRUG CLASSIFICATION; DRUG SAFETY; EXTRAVASATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN IRRITATION; TISSUE INJURY; TREATMENT OUTCOME;

EID: 84899102263     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013510546     Document Type: Review

References (22)

1. Ascherman J. Knowles S. Attkiss K. (2000) Docetaxel (Taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 45: 438–441.
2. Berghammer P. Pohnl R. Baur M. Dittrich C. (2001) Docetaxel extravasation. Support Care Cancer 9: 131–134.
3. Celgene Corporation (2012) Abraxane® Prescribing information. Summit, NJ: Celgene Corporation.
4. Cifuentes L. Ring J. Brockow K. (2012) Extravasation of docetaxel. J Dtsch Dermatol Ges. DOI: 10.111/j.1610-0387.2012.07973.x.
5. Dorr R. Snead K. Liddil J. (1996) Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78: 152–156.
6. El Saghir N. Otrock Z. (2004) Docetaxel extravasation into the normal breast during breast cancer treatment. Anticancer Drugs 15: 401–404.
7. Gentilhomme E. Neveux Y. Hua A. Thiriot C. Faure M. Thivolet J. (1992) Action of bis(betachloroethyl) sulphide (BCES)on human epidermis reconstituted in culture: morphological alterations and biochemical depletion of glutathione. Toxicol In Vitro 6: 139–147.
8. Ho C. Yang C. Chu C. (2003) Vesicant-type reaction due to docetaxel extravasation. Acta Derm Venereol. DOI: 10.1080/00015550310013709.
9. Kawano S. Kondoh H. Ishikawa K. Koizumi S. Kadota T. Takahashi N. (1994) Irritability study of paclitaxel in rabbit ear vein. J Toxicol Sci 19: 123– 130.
10. Kramer F. Schippert C. Rinnau F. Hillemanns P. Park-Simon T. (2011) The first description of docetaxel-induced recall inflammatory skin reaction after previous drug extravasation. Ann Pharmacother 45: e11.
11. Langstein H. Duman H. Seelig D. Butler C. Evans G. (2002) Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 49: 369–374.
12. Neuss M. Polovich M. McNiff K. Esper P. Gilmore T. LeFebvre K. et al. (2013) 2013 Updated American Society of Clinical Oncology / Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. J Oncol Pract 9: 5s–13s.
13. Pfizer (2011) Paclitaxel Prescribing information. New York, NY: Pfizer.
14. Papirmeister B. Gross C. Meier H. Petrali J. Johnson J. (1985) Molecular basis for mustard-induced vesication. Fundam Appl Toxicol 5: S134–S149.
15. Polovich M. Whitford J. Olsen M. (2009) Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (Third edition). Pittsburg, PA: Oncology Nursing Society.
16. Raley J. Geisler J. Buekers T. Sorosky J. (2000) Docetaxel extravasation causing significant delayed tissue injury. Gynecol Oncol 78: 259-260.
17. Sauerland C. Engelking C. Wickham R. Corbi D. (2006) Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 33: 1134–1141.
18. Sanofi-aventis US LLC (2010) Jevtana® Prescribing information. Bridgewater, NJ: Sanofi-aventis US LLC.
19. Sanofi-aventis US LLC (2011) Taxotere® Prescribing information. Bridgewater, NJ: Sanofi-aventis US LLC.
20. Stanford B. Hardwicke F. (2003) A review of clinical experience with paclitaxel extravasations. Support Care Cancer 11: 270–277.
21. Una E. Cuadrillero F. Lopez-Lara F. (2009) Drug extravasation: a dreaded complication. BMJ Case Rep. DOI: 10.1136/bcr.09.2008.0887.
22. Wickham R. Engelking C. Sauerland C. Corbi D. (2006) Vesicant extravasation part II: evidence-based management and continuing controversies. Oncol Nurs Forum 33: 1143–1150.